Skip to content

Effect of excimer lamp in alopecia areta

To evaluate efficacy and safety of 308nm excimer lamp in treatment of patchy alopecia areata on scalp - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073190
Enrollment
34
Registered
2024-09-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L638- Other alopecia areata

Interventions

Intervention1: Excimer lamp 308 nm: The patch allocated to treatment intervention will receivesessions of excimer lamp twice a week. The dosage of excimer lamp will be determined based on Minimal Ery

Sponsors

Topiwala National medical college and BYL Nair charitable hospital Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient with a diagnosis of patch type of alopecia areata Patient with at least 2 to maximum 5 patches of alopecia areata with a maximum difference of 1 cm in the largest dimension of the largest two patches. Size of the patches between 2 cm to 3.5 cm at largest diameter (arbitrarily decided based on the size of the stencil available with the lamp) Duration of lesions less than 6 months

Exclusion criteria

Exclusion criteria: Patient with a history of existing skin diseases affecting the scalp such as psoriasis and patient with evidence of infection in treated area Pregnant and lactating women Inactive late stage History of photosensitive dermatoses Sisaipho, ophiasis pattern of hair loss Patients who have received topical immunosuppresants/ immunomodulators like topical steroid, tacrolimus, calcipotriol,etc or topical irritants like salicylic acid, benzoyl peroxide,anthralin, tretinoin etcin last 2 weeks Patients who have received systemic immunosuppresants/ immunomodulatorslike methotrexate, cyclosporine, oral steroids, azathioprine, etcin last 6 weeks Patients who have received interventional treatment in last 1 month (ablative or nonablative laser, excimer laser etc) Patients who have received topical immunotherapy with contact allergens in last 1 month

Design outcomes

Primary

MeasureTime frame
Study outcome measures will be CLINICAL- A. Presence of positive or negative alopecia areata hair pull test B. Presence or absence of short regrowing hair as evident clinically C. 4-point scale for person hair growth by independent assessor D. Surface area of alopecic patch TRICOSCOPIC A. Yellow dots B. Black dot C. Broken hair D. Tapering hair (exclamation mark hair) E. Coudability hair F. Short vellus hair G. Pigtail hair H. Pohl-pinkus constrictions I. ‘I’ hairTimepoint: Outcome measures will be measured at baseline, then at 4,8,12 and 16 weeks

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactAtul Dongre

Topiwala National medical college, Mumbai

atul507@yahoo.co.in9021080398

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026